Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 11, 2007. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,225,000 ordinary shares.
- Purchase Price: 1,299.4729 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.15% of total voting rights).
- Shares in Issue: 5,508,706,895 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,225,000 shares purchased on December 11, 2007. Consequently, the total number of shares held in Treasury increased to 504,194,158.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,508,706,895) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (504,194,158) and its impact on the percentage of total voting rights (9.15%).
- Note that this transaction was executed at a specific price of 1,299.4729 pence per share.